Clinical Trials Logo
  1. Home
  2. Cardiac Amyloidosis
  3. NCT06096675

CAPACITY (Cardiac Amyloidosis and Physical ACtivITY) Study — CAPACITY  

Cardiac Amyloidosis Clinical Trial

Official title:
Pilot Study Evaluating Supervised Cardiac Rehabilitation in Patients With Cardiac Amyloidosis

Clinical Trial Summary

Exercise training in patients with heart failure and preserved ejection fraction (HFpEF) has been associated with an improvement in cardiorespiratory fitness and quality of life.

Clinical Trial Description

The Atrium Health cardiac rehabilitation program delivers a comprehensive approach to improve cardiac performance including supervised exercise programs and has the ideal infrastructure to offer cardio-oncology rehabilitation (CORE) to all our cancer patients in the future. Currently neither CORE nor cardiac rehabilitation for HFpEF are covered by insurance, and hence the targeting of a higher risk cancer and non-cancer population of cardiac amyloidosis patients to objectively measure the benefits of a supervised exercise program ultimately to expand eligibility to all cancer patients and shape the treatment and payor landscape in the future. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06096675
Study type Interventional
Source Wake Forest University Health Sciences
Contact Dana B Amaro, RN
Phone 704-355-4692
Email Dana.Amaro@atriumhealth.org
Status Recruiting
Phase N/A
Start date January 22, 2024
Completion date January 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04459169 - Cardiac Amyloidosis : Diagnostic Using Red Flag Signals
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Recruiting NCT06034405 - Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis
Recruiting NCT04915235 - Prevalence and Prognosis of Cardiac Amiloidosis in Turkey
Recruiting NCT02966522 - Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis Phase 2
Terminated NCT03333551 - Cardiac Uptake of 18F Florbetapir in Patients Undergoing Chemotherapy Phase 4
Recruiting NCT04105634 - Molecular Imaging of the Underlying Mechanism of Cardiotoxicity in Patients With Light Chain Amyloidosis Using PET/CT Early Phase 1
Recruiting NCT05139797 - Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening)
Not yet recruiting NCT05593679 - A Multi-center Cardiac PYP Scan Registry in Taiwan.
Not yet recruiting NCT04146415 - Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera N/A
Recruiting NCT03626584 - PET/MR Imaging In Patients With Cardiac Amyloidosis
Recruiting NCT04856267 - Exploration of Arrhythmia Burden in Cardiac Amyloidosis Using Implantable Loop Recorders
Completed NCT03119558 - PET/MRI Evaluation of Cardiac Amyloid Early Phase 1
Recruiting NCT02798705 - Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Not yet recruiting NCT04387344 - Morpho-functional Cardiac Modifications in Treated Mutated Transthyretin Cardiac Amyloidosis
Recruiting NCT06129656 - Cardiac Amyloidosis Registry of University Hospital Leipzig
Terminated NCT01683825 - Imaging Cardiac Amyloidosis: A Pilot Study Using F-18 Florbetapir Positron Emission Tomography Phase 4
Withdrawn NCT04363294 - Targeted Testing for ATTR Among Aortic Stenosis Patients-Pilot N/A
Not yet recruiting NCT04661800 - Study of Olfactory Disorders in Patients With Cardiac Amyloidosis N/A
Terminated NCT03232632 - Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. Early Phase 1